{
    "nct_id": "NCT04200417",
    "official_title": "Phase I Study of Transarterial Chemoembolization of Lung Metastases",
    "inclusion_criteria": "* Lung, endobronchial, pleural, or mediastinal metastases that are not responding to systemic chemotherapy, and that are not amenable to ablation, resection, or SBRT.\n* At least 18 years old.\n* ECOG performance status 0 or 1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Primary lung cancer\n* >50% of a lung is replaced with tumor\n* Oxygen saturation <92% on room air\n* FEV1 <60%\n* Pulmonary hypertension (diagnosed or suspected on echocardiography, CT, MRI, or direct pressure measurement)\n* Recent pulmonary embolism (within 3 months)\n* Pulmonary arteriovenous malformation\n* Active lung infection (pneumonia, empyema, or lung abscess requiring therapy within 1 month)\n* Symptomatic heart failure (dyspnea, volume overload)\n* Left bundle branch block (contraindication to pulmonary angiography)\n* Renal failure (eGFR <30 mL/min/1.73m^2)\n* Pregnancy\n* Breastfeeding\n* Altered mental status that would interfere with consent or follow-up\n* Platelets < 100,000 (after transfusion, if needed)\n* INR>2 (after transfusion, if needed)\n* Hemoglobin <7 (after transfusion, if needed)\n* Hyperthyroidism (contraindication to lipiodol)\n* Planned radioactive iodine imaging or therapy (contraindication to lipiodol)\n* Allergy to lipiodol or mitomycin\n* Allergy to iodinated contrast that can not be treated with steroid / diphenhydramine premedication\n* Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results",
    "miscellaneous_criteria": ""
}